Diclofenac injection - Javelin Pharmaceuticals

Drug Profile

Diclofenac injection - Javelin Pharmaceuticals

Alternative Names: Dyloject

Latest Information Update: 04 Jan 2015

Price : $50

At a glance

  • Originator Javelin Pharmaceuticals
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Postoperative pain

Most Recent Events

  • 30 Dec 2014 Registered for Postoperative pain in USA (IV)
  • 31 Dec 2013 Hospira receives a second complete response letter from the US FDA for injectable diclofenac in Postoperative pain
  • 02 Jul 2010 Javelin Pharmaceuticals has been acquired by Hospira
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top